Global Reperfusion Treatment Market, By Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulphide Treatment, and Others), By Injury Type (Heart Injury, Kidney Injury, Intestine Injury, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,546.7 Million in 2023, and is expected to exhibit a CAGR of 4.7% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing adopton of strategies by key market players like collaboration is expected to drive the global reperfusion treatment market growth over the forecast period. For instance, on July 20, 2023, RenovoRx, Inc., a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd., a clinical-stage immuno-oncology company, announced a strategic research collaboration to enhance the delivery of Imugene's oncolytic virus therapy with RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of challenging tumors.
Global Reperfusion Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and has a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding the transportation of drugs from one place to another.
COVID-19 had positive impact on the global reperfusion treatment market due to increasing need for cardiac treatments with perfusion therapy during COVID-19. For instance, on February 14, 2022, according to an article published by American College of Cardiology Foundation, ollowing 15–35 hours of enhanced external counterpulsation (EECP) therapy, both patients with and without coronary artery disease in a study of long-term COVID-19 patients showed improvement in symptoms including fatigue, breathing issues, and chest discomfort. EECP is a non-invasive technique that improve cardiac and cerebral perfusion. EECP is a non-invasive, disease-modifying treatment that can enhance endothelial function where nutrients, such as fish oil, antioxidants, L-arginine, folic acid and soy protein have shown an improvement in endothelial function that can mediate, at least partially, the cardioprotective effects of these substances
Global Reperfusion Treatment Market: Key Developments
Increasing government approvals for perfusion treatment is expected to drive the market growth.
For instance, on April 26, 2020, XVIVO is the only medical technology company has Perfusion System with Steen Solution Perfusate, a device that can temporarily ventilate, oxygenate, and pump preservation solution through lungs that were initially deemed unsuitable for transplanthad been approved by the U.S. Food and Drug Administration. The tool enables the transplant team to more thoroughly evaluate lung function to better understand how the organs function when these are perfused with a solution outside the body to better assess whether the lungs can then be viable for transplant.
Browse 46 Market Data Tables and 50 Figures spread through 260 Pages and in-depth TOC on Global Reperfusion Treatment Market, By Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulphide Treatment, and Others), by Injury Type (Heart Injury, Kidney Injury, Intestine Injury, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/reperfusion-treatment-market-4248
Key Takeaways of the Global Reperfusion Treatment Market:
- Global reperfusion treatment market is expected to exhibit a CAGR of 4.7% during the forecast period owing to using microbubbles and diagnostic ultrasound, new therapeutic effects to improve tumor blood perfusion have been discovered. For instance, on March 23, 2023, according to an article published by Springer Nature, a scientific journal stated that demonstrated the 0.26 MPa and 1 kHz USMB treatment significantly increased tumor perfusion, resulting in a 20.29% rise in contrast-enhanced ultrasound peak intensity and a 21.42% increase in the perfusion area for more than 4 hours. The increased in a dox delivery to tumors by about 3.12 times more than the control. ELISA results revealed increase in vasodilators and inflammatory factors 4 hours after treatment, indicating that the inflammatory response is crucial to the sononeoperfusion effect.
- Among segmentation, Therapeutic Hypothermia from treatment type segment is expected to dominate the global reperfusion treatment market over the forecast period. For instance, on August 6, 2023, Cardiovascular Learning Network published, The Journal of Invasive Cardiology an article explaining how home monitoring of tissue perfusion post-PTA predicts the clinical outcome of CLTI patients. There are two important points: the first is that tissue perfusion differs between patients with and without clinical improvement. Physicians can keep track of a patient's recovery pattern. During the first few weeks of treatment, patients had a good response. However, on day 22, there was a decline in their hyperspectral imaging, and their values were incorrect. That might be a sign that something is wrong, and thus, there can be be an early re-occlusion. Physicians can identify issues earlier and address them more quickly. On the other hand, if a patient gets better, they might not require a 6-week follow-up at the outpatient clinic. Physicians could tailor the follow-up based on the patient's progress with home monitoring, of course which will also save time and money.
- Major players operating in the global reperfusion treatment market include Corline Biomedical AB, SBI Holdings Inc., Pharming Group NV, Mallinckrodt Pharmaceuticals, MIFCOR, Inc., CFM Pharma Holding B.V, Balmes Transplantation SAS, Revive Therapeutics Ltd, Faraday Pharmaceuticals, Radikal Therapeutics Inc, Amyndas Pharmaceuticals, com, Inc, Angion Biomedica Corp, Young Therapeutics, LLC, Ischemix, Stealth Biotherapeutics Inc and Bolder Bio Technology Inc.
